Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Trial Investigating Platinum and Taxane Chemotherapy in Metastatic Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

NCT06439225 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.

NCT NCT06439225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06439225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Trial Investigating Platinum and Taxane Chemotherapy in Metastatic Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
Lead sponsor
Canadian Cancer Trials Group
Phase
Phase 3
Overall status
Recruiting
Start date
December 30, 2024
Completion date
March 31, 2030
Enrollment
236 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer, metastatic prostate cancer